BrainCool AB (publ): Utilization of BrainCell in Thrombectomy following Acute Ischemic Stroke: A Scientific Clinical Study" has now been released in the Journal of Stroke & Vascular Neurology
Kurs
-0,45%
Likviditet
0,87 MSEK
Prenumeration
Kalender
| Tid* | ||
| 2025-02-11 | 18:00 | Bokslutskommuniké 2024 |
| 2024-11-01 | - | Kvartalsrapport 2024-Q3 |
| 2024-08-15 | - | Kvartalsrapport 2024-Q2 |
| 2024-06-26 | - | Årsstämma |
| 2024-04-26 | - | X-dag ordinarie utdelning BRAIN 0.00 SEK |
| 2024-04-15 | - | Kvartalsrapport 2024-Q1 |
| 2024-02-29 | - | Bokslutskommuniké 2023 |
| 2023-11-30 | - | Kvartalsrapport 2023-Q3 |
| 2023-08-31 | - | Kvartalsrapport 2023-Q2 |
| 2023-05-31 | - | Kvartalsrapport 2023-Q1 |
| 2023-05-12 | - | X-dag ordinarie utdelning BRAIN 0.00 SEK |
| 2023-05-11 | - | Årsstämma |
| 2023-02-28 | - | Bokslutskommuniké 2022 |
| 2023-02-15 | - | Extra Bolagsstämma 2022 |
| 2022-11-30 | - | Kvartalsrapport 2022-Q3 |
| 2022-08-31 | - | Kvartalsrapport 2022-Q2 |
| 2022-05-31 | - | Kvartalsrapport 2022-Q1 |
| 2022-05-12 | - | X-dag ordinarie utdelning BRAIN 0.00 SEK |
| 2022-05-11 | - | Årsstämma |
| 2022-02-28 | - | Bokslutskommuniké 2021 |
| 2021-11-30 | - | Kvartalsrapport 2021-Q3 |
| 2021-08-26 | - | Kvartalsrapport 2021-Q2 |
| 2021-05-31 | - | Kvartalsrapport 2021-Q1 |
| 2021-04-16 | - | X-dag ordinarie utdelning BRAIN 0.00 SEK |
| 2021-04-15 | - | Årsstämma |
| 2021-02-26 | - | Bokslutskommuniké 2020 |
| 2020-11-27 | - | Kvartalsrapport 2020-Q3 |
| 2020-08-28 | - | Kvartalsrapport 2020-Q2 |
| 2020-07-01 | - | X-dag ordinarie utdelning BRAIN 0.00 SEK |
| 2020-06-30 | - | Årsstämma |
| 2020-05-29 | - | Kvartalsrapport 2020-Q1 |
| 2020-04-29 | - | X-dag ordinarie utdelning BRAIN 0.00 SEK |
| 2020-02-28 | - | Bokslutskommuniké 2019 |
| 2019-11-08 | - | Kvartalsrapport 2019-Q3 |
| 2019-08-30 | - | Kvartalsrapport 2019-Q2 |
| 2019-06-17 | - | Årsstämma |
| 2019-04-08 | - | X-dag ordinarie utdelning BRAIN 0.00 SEK |
| 2019-02-28 | - | Bokslutskommuniké 2018 |
| 2018-11-16 | - | Kvartalsrapport 2018-Q3 |
| 2018-08-27 | - | Kvartalsrapport 2018-Q2 |
| 2018-07-25 | - | Extra Bolagsstämma 2018 |
| 2018-05-09 | - | Kvartalsrapport 2018-Q1 |
| 2018-04-19 | - | X-dag ordinarie utdelning BRAIN 0.00 SEK |
| 2018-04-18 | - | Årsstämma |
| 2018-02-16 | - | Bokslutskommuniké 2017 |
| 2017-11-23 | - | Kvartalsrapport 2017-Q3 |
| 2017-08-10 | - | Kvartalsrapport 2017-Q2 |
| 2017-06-29 | - | Årsstämma |
| 2017-05-15 | - | Kvartalsrapport 2017-Q1 |
| 2017-04-24 | - | Extra Bolagsstämma 2017 |
| 2017-04-12 | - | X-dag ordinarie utdelning BRAIN 0.00 SEK |
| 2017-02-14 | - | Bokslutskommuniké 2016 |
| 2016-11-10 | - | Kvartalsrapport 2016-Q3 |
| 2016-08-25 | - | Kvartalsrapport 2016-Q2 |
| 2016-05-10 | - | Kvartalsrapport 2016-Q1 |
| 2016-04-14 | - | Årsstämma |
| 2016-03-27 | - | X-dag ordinarie utdelning BRAIN 0.00 SEK |
| 2016-01-28 | - | Bokslutskommuniké 2015 |
| 2015-10-22 | - | Kvartalsrapport 2015-Q3 |
| 2015-08-26 | - | Kvartalsrapport 2015-Q2 |
| 2015-04-28 | - | Kvartalsrapport 2015-Q1 |
| 2015-03-27 | - | X-dag ordinarie utdelning BRAIN 0.00 SEK |
| 2015-03-26 | - | Årsstämma |
| 2015-01-27 | - | Bokslutskommuniké 2014 |
| 2014-10-20 | - | Kvartalsrapport 2014-Q3 |
| 2014-08-19 | - | Kvartalsrapport 2014-Q2 |
| 2014-06-26 | - | X-dag ordinarie utdelning BRAIN 0.00 SEK |
| 2014-06-25 | - | Årsstämma |
| 2014-04-14 | - | Extra Bolagsstämma 2014 |
Beskrivning
| Land | Sverige |
|---|---|
| Lista | First North Stockholm |
| Sektor | Hälsovård |
| Industri | Medicinteknik |
BrainCell is a uniqe combination of the use of RhinoChill® och BrainCool™ System.
The study, titled "COmbination of Targeted Temperature Management and Thrombectomy after acute Ischemic Stroke (COTTIS)," presents a groundbreaking approach that holds the potential to revolutionize stroke treatment protocols. The results of this pioneering study, released just yesterday 1), showcase the remarkable synergistic effects of combining targeted temperature management and thrombectomy techniques. These findings not only offer new insights into enhancing post-stroke care but also hold promising implications for regulatory approval in Germany and other countries. The COTTIS1 study marks a pivotal moment in stroke research, raising optimism for improved outcomes for acute ischemic stroke patients worldwide.
CEO Martin Waleij comments
“We are happy to share a notable breakthrough in acute ischemic stroke research as the pilot results of the COTTIS1 study have been published in the prestigious Journal of Stroke & Vascular Neurology. Our attention has now shifted towards backing the upcoming COTTIS2 trial, scheduled to commence in September across five sites in Germany.”
Reference:
1. https://svn.bmj.com/content/svnbmj/early/2023/08/22/svn-2023-002420.full.pdf
Contacts
For more information
Martin Waleij - CEO
+46 - 733 -93 70 76
E-mail: martin.waleij@braincool.se
About Us
BrainCool AB (publ) is an innovative medical device company that develops, markets, and sells leading medical cooling systems for indications and areas with significant medical benefits within the healthcare sector. BrainCool AB (publ) is based in Lund, Sweden, and its share is listed on Nasdaq First North Growth Market, named “BRAIN”.
Eminova Fondkommission AB is the company’s Certified Adviser.